Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
PURPOSE: To present the results of a prospective phase II study in esophageal carcinoma. PATIENTS AND METHODS: Patients received single doses of 1.8 Gy up to 27 Gy, then concomitant boost to a total of 50.4 Gy (PTV2 [planning target volume], single dose 1.8 Gy) and 64.8 Gy (PTV1, single dose 1.2 Gy...
Main Authors: | Brunner, T, Rupp, A, Melzner, W, Grabenbauer, G, Sauer, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2008
|
Similar Items
-
Concomitant chemoradiotherapy, brachytherapy, and parametrial boost versus concomitant chemoradiation and brachytherapy alone in locally advanced cervical carcinoma: A prospective and comparative study
by: Saptarshi Banerjee, et al.
Published: (2023-04-01) -
Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation.
by: Tinkl, D, et al.
Published: (2009) -
Endoluminal vacuum therapy of esophageal perforations
by: Mustafa Abdulsada, MBBS, et al.
Published: (2020-01-01) -
A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
by: Brunner, T, et al.
Published: (2008) -
A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
by: Brunner, T, et al.
Published: (2008)